Enovis Corporation (ENOV)

Enovis Corp. stock has declined, falling 41.82% over six months. In February 2026, the company announced its financial results, beating EPS expectations but missing on revenue, with analysts maintaining a 'Moderate Buy' rating. In March 2026, the company's Chief Administrative Officer purchased ENOV shares, and the First Quarter 2026 Results Conference Call is scheduled for May 7, 2026.

Enovis Corp. typically experiences a peak in its sales during the fourth quarter of the fiscal year. However, general economic conditions and other external factors can influence these seasonal variations.

Enovis Corp. is a global medical technology company focused on orthopedics, operating within the Healthcare sector and Medical Devices industry. It develops solutions to enhance patient outcomes and restore motion, structured around two segments: Prevention & Recovery and Reconstructive. The Prevention & Recovery segment offers products for musculoskeletal conditions, including brands like DonJoy and Aircast. The Reconstructive segment provides joint products and surgical tools, including the ARVIS Augmented Reality System.

Enovis has a significant global presence with over 7,000 employees and 30 facilities worldwide. Its brands are sold in over 50 countries through subsidiaries or distributors. Enovis has a direct presence in regions including the USA, Europe, Canada, South America, Asia Pacific, Central Europe, the Middle East, and South Africa. Its global headquarters are located in Wilmington, Delaware, U.S.

Enovis maintains a reputation as an innovation-driven medical technology company committed to improving lives and restoring motion. The company focuses on developing clinically differentiated solutions and partnering with healthcare professionals. Key events include the acquisition of LimaCorporate, ongoing innovation in orthopedic technologies, and new product launches like the ARVIS Augmented Reality System and OrthoDrive Impactor. While the company's stock has underperformed and it faced goodwill impairment charges in Q3 2025, there have been no explicit negative events directly impacting its brand reputation reported in the past year.

Enovis Corp. has a diverse ownership structure, with institutional investors holding a dominant stake. As of April 2025, institutional investors held 93.98% of the shares, while individual investors held 4.34%, and insiders held 1.68%. More recent data from April 2026 indicates institutional ownership at 98.45% and insider ownership at 2.70%. Major institutional shareholders include BlackRock, Inc. and Vanguard Group Inc, while significant individual shareholders include Bdt Capital Partners LLC and Steven M. Rales.